239 related articles for article (PubMed ID: 28413427)
1. Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults.
Fries L; Shinde V; Stoddard JJ; Thomas DN; Kpamegan E; Lu H; Smith G; Hickman SP; Piedra P; Glenn GM
Immun Ageing; 2017; 14():8. PubMed ID: 28413427
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.
Glenn GM; Fries LF; Thomas DN; Smith G; Kpamegan E; Lu H; Flyer D; Jani D; Hickman SP; Piedra PA
J Infect Dis; 2016 Feb; 213(3):411-22. PubMed ID: 26259809
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine.
Glenn GM; Smith G; Fries L; Raghunandan R; Lu H; Zhou B; Thomas DN; Hickman SP; Kpamegan E; Boddapati S; Piedra PA
Vaccine; 2013 Jan; 31(3):524-32. PubMed ID: 23153449
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
[TBL] [Abstract][Full Text] [Related]
7. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
Falloon J; Ji F; Curtis C; Bart S; Sheldon E; Krieger D; Dubovsky F; Lambert S; Takas T; Villafana T; Esser MT
Vaccine; 2016 May; 34(25):2847-54. PubMed ID: 27102821
[TBL] [Abstract][Full Text] [Related]
8. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
Leroux-Roels I; Van Ranst M; Vandermeulen C; Abeele CV; De Schrevel N; Salaun B; Verheust C; David MP; Kotb S; Hulstrøm V
J Infect Dis; 2024 Feb; 229(2):355-366. PubMed ID: 37699064
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial.
F Schwarz T; Hwang SJ; Ylisastigui P; Liu CS; Takazawa K; Yono M; Ervin JE; Andrews CP; Fogarty C; Eckermann T; Collete D; de Heusch M; De Schrevel N; Salaun B; Lambert A; Maréchal C; Olivier A; Nakanwagi P; Lievens M; Hulstrøm V
J Infect Dis; 2023 Dec; ():. PubMed ID: 38099559
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Leroux-Roels I; Davis MG; Steenackers K; Essink B; Vandermeulen C; Fogarty C; Andrews CP; Kerwin E; David MP; Fissette L; Vanden Abeele C; Collete D; de Heusch M; Salaun B; De Schrevel N; Koch J; Verheust C; Dezutter N; Struyf F; Mesaros N; Tica J; Hulstrøm V
J Infect Dis; 2023 Mar; 227(6):761-772. PubMed ID: 35904987
[TBL] [Abstract][Full Text] [Related]
11. Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs.
Glenn GM; Fries LF; Smith G; Kpamegan E; Lu H; Guebre-Xabier M; Hickman SP; Flyer D
Vaccine; 2015 Nov; 33(47):6488-92. PubMed ID: 26319066
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V
Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
Schwarz TF; McPhee RA; Launay O; Leroux-Roels G; Talli J; Picciolato M; Gao F; Cai R; Nguyen TL; Dieussaert I; Miller JM; Schmidt AC
J Infect Dis; 2019 Oct; 220(11):1816-1825. PubMed ID: 31418022
[TBL] [Abstract][Full Text] [Related]
14. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
[TBL] [Abstract][Full Text] [Related]
15. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
Aliprantis AO; Shaw CA; Griffin P; Farinola N; Railkar RA; Cao X; Liu W; Sachs JR; Swenson CJ; Lee H; Cox KS; Spellman DS; Winstead CJ; Smolenov I; Lai E; Zaks T; Espeseth AS; Panther L
Hum Vaccin Immunother; 2021 May; 17(5):1248-1261. PubMed ID: 33121346
[TBL] [Abstract][Full Text] [Related]
16. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
Langley JM; Sales V; McGeer A; Guasparini R; Predy G; Meekison W; Li M; Capellan J; Wang E
Vaccine; 2009 Sep; 27(42):5913-9. PubMed ID: 19651171
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants.
Muňoz FM; Swamy GK; Hickman SP; Agrawal S; Piedra PA; Glenn GM; Patel N; August AM; Cho I; Fries L
J Infect Dis; 2019 Oct; 220(11):1802-1815. PubMed ID: 31402384
[TBL] [Abstract][Full Text] [Related]
20. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
